Bovine adenovirus

Lore & Background

Bovine adenovirus is a pathogen of cattle that infects the gastrointestinal and respiratory tracts, with clinical signs more common in younger animals as maternal antibodies wane from as young as two weeks old. Gastrointestinal signs include diarrhoea, reduced appetite, and abdominal distension; respiratory signs include coughing, serous nasal discharge, dyspnea, and tachypnea. Signs may worsen if a secondary infection occurs, and generalized disease can present with pyrexia, weight loss, depression, weakness, lymphadenopathy, lethargy, and even sudden death.

Definitive diagnosis requires a fourfold rise in antibody titre over the course of the disease, as the presence of the virus alone is insufficient due to its occurrence in healthy cattle. Virus isolation is the only method to identify the serotype. Postmortem examination may reveal lesions in the gastrointestinal or respiratory tract and enlarged lymph nodes.

Treatment is symptomatic when possible, with antibiotics indicated to prevent secondary infection. Control measures include ensuring calves receive adequate colostrum at birth, separating different age groups, and providing good ventilation and clean bedding. Vaccination of young cattle can reduce the severity and incidence of disease, but multiple doses are required, usually combined with other agents, and the vaccine is not available worldwide.

Reader's Guide

Bovine adenovirus is significant as a widespread pathogen of cattle, particularly in Africa and Central America, where it contributes to respiratory and gastrointestinal disease. Its ability to cause subclinical infection complicates diagnosis, as virus isolation alone cannot confirm disease—only a fourfold rise in antibody titre is definitive. The virus's role in enzootic pneumonia and its potential for persistent infection, leading to prolonged shedding, underscore its impact on herd health. Control relies on colostrum management, biosecurity, and vaccination, though vaccine availability is limited. Understanding BAdV is important for veterinary practitioners managing cattle health, especially in young animals where maternal antibody waning increases susceptibility. The virus's 10 serotypes and variable clinical presentation highlight the need for serotype-specific identification via virus isolation to guide control strategies.

Did You Know?

• Bovine adenovirus has 10 recognized serotypes.
• The virus can be isolated from healthy cattle, so its presence alone does not confirm disease.
• Infected cattle shed the virus for approximately 10 days, but some become persistently infected and excrete it much longer.
• Vaccination is not available worldwide.

Taxonomy & Global Reach

Bovine adenovirus, commonly abbreviated as BAdV, is a pathogen belonging to the Adenoviridae family that specifically targets cattle. To date, ten distinct serotypes have been formally recognised, each capable of producing a somewhat different clinical picture in affected herds. The virus enjoys a truly worldwide distribution, meaning no continent is entirely free of its presence. Nevertheless, certain regions bear a disproportionate burden of infection. Africa and Central America stand out as areas where BAdV is particularly prevalent, likely reflecting the density of cattle populations and local husbandry practices in those parts of the world. The existence of multiple serotypes adds a layer of complexity to both surveillance and control efforts, since a single serotype may be responsible for gastrointestinal disease while another contributes to respiratory illness or even enzootic pneumonia. This serotype-dependent variation means that veterinarians working in different regions may encounter very different presentations of what is, fundamentally, the same viral family member. Understanding which serotypes circulate locally remains a critical step in any regional disease-management strategy.

Clinical Spectrum & Diagnostic Hurdles

The clinical picture of BAdV infection is remarkably broad, shifting depending on which serotype is involved. In its most common form, the virus attacks either the gastrointestinal tract or the respiratory system, though ocular involvement and generalised systemic illness are also documented. Younger animals are disproportionately affected, with cases emerging as early as two weeks of age once maternal antibody protection begins to fade. Gastrointestinal presentations include diarrhoea, loss of appetite, and a visibly distended abdomen. Respiratory disease manifests through persistent coughing, clear nasal discharge, laboured breathing, and an elevated respiratory rate. When a secondary bacterial infection takes hold, the clinical picture deteriorates markedly. In severe generalised cases, affected cattle may show fever, progressive weight loss, marked depression, weakness, swollen lymph nodes, and profound lethargy, and even sudden death has been reported. Diagnosing BAdV is notoriously difficult because the virus can be recovered from perfectly healthy cattle, meaning its mere presence does not confirm active disease. A definitive diagnosis requires demonstrating a fourfold rise in antibody titre over the course of the illness. Identifying the specific serotype demands virus isolation in the laboratory, and postmortem examination of fallen animals may reveal characteristic lesions in the gut or lungs alongside enlarged lymph nodes.

Treatment Approaches & Herd Management

Because no specific antiviral therapy exists for BAdV, clinical management focuses on supporting the animal through the illness. Symptomatic treatment is the cornerstone of care, and where secondary bacterial infections are suspected or confirmed, a course of antibiotics is typically administered to prevent the condition from worsening. Prevention, however, offers far more promise than cure. Ensuring that newborn calves receive an adequate volume of quality colostrum is one of the most effective single measures, as it provides the passive immunity that shields young stock during the vulnerable window when maternal antibodies are waning. Beyond colostrum management, practical husbandry adjustments play a significant role in reducing transmission. Separating calves from older cattle, maintaining good airflow and ventilation in housing, and providing clean, dry bedding all help lower the incidence of disease within a herd. Vaccination of young cattle represents another important tool, capable of reducing both the frequency and the severity of outbreaks. In practice, the vaccine requires multiple doses to build adequate protection and is typically administered in combination with agents targeting other common bovine pathogens. A notable limitation is that the vaccine is not available in every country, leaving some regions without this critical preventive option.

Shedding, Persistence & the Silent Carrier Problem

One of the most challenging aspects of BAdV from a control perspective is the way the virus moves through a herd. After initial infection, cattle typically shed the virus in their respiratory secretions or faeces for a period of roughly ten days, during which they can transmit the pathogen to susceptible animals. However, a subset of infected cattle becomes persistently infected, meaning they continue to excrete the virus well beyond that initial ten-day window, acting as long-term reservoirs within the population. This persistent shedding complicates eradication efforts, as the virus can linger in a herd long after the acute clinical phase has passed. The situation is further complicated by the fact that BAdV can be isolated from cattle that show absolutely no signs of illness. These asymptomatic carriers are invisible to routine observation yet still capable of spreading the virus to vulnerable young animals. This dual reality—healthy-looking cattle harbouring the pathogen alongside persistently infected individuals—makes it extremely difficult to identify and remove sources of infection from a herd. It also explains why simple detection of the virus in a sample is insufficient for diagnosis and why serological confirmation through paired antibody testing remains essential for proving active disease rather than mere exposure.